SalioGen Therapeutics, a privately held biotechnology company developing Gene Coding, a new category of genetic medicine, announced the completion of an oversubscribed and up-sized $115 million Series B financing.

The financing round was co-led by GordonMD Global Investments and EPIQ Capital Group. Additional new investors included Fidelity Management & Research Company LLC, funds and accounts advised by T. Rowe Price Associates, Inc., D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, the RD Fund (the venture arm of Foundation Fighting Blindness), and others. The round also included continued support from PBM Capital, which led the company's Series A round.